TrialJournal for immunotherapy of cancer2020

KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in

Pier Francesco Ferrucci et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.